Julie K Schwarz
Overview
Explore the profile of Julie K Schwarz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
2249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tortelli B, Contreras J, Markovina S, Ding L, Wylie K, Schwarz J
JCI Insight
. 2025 Feb;
PMID: 39903534
The standard-of-care treatment of locally advanced cervical cancer includes pelvic radiation therapy with concurrent cisplatin-based chemotherapy and is associated with a 30-50% failure rate. New prognostic and therapeutic targets are...
2.
Fowle-Grider R, Rowles 3rd J, Shen I, Wang Y, Schwaiger-Haber M, Dunham A, et al.
Nature
. 2024 Dec;
636(8043):737-744.
PMID: 39633044
Fructose consumption has increased considerably over the past five decades, largely due to the widespread use of high-fructose corn syrup as a sweetener. It has been proposed that fructose promotes...
3.
McKinnish T, Kuroki L, Schwarz J, Mazul A
J Low Genit Tract Dis
. 2024 Dec;
29(1):48-54.
PMID: 39620893
Objectives: This article describe trends in the incidence and mortality of cervical (CC) and anal (AC) cancers by race and neighborhood socioeconomic status. Methods: The Surveillance, Epidemiology, and End Results...
4.
Shi V, Grover S, Huang Y, Thaker P, Kuroki L, Powell M, et al.
Int J Gynecol Cancer
. 2024 Apr;
34(6):808-816.
PMID: 38684343
Objective: Recurrence remains a significant clinical problem for patients with cervical cancer, and early detection may improve outcomes. Serum squamous cell carcinoma antigen (SCCA) is a biomarker of prognosis and...
5.
Waters M, Inkman M, Jayachandran K, Kowalchuk R, Robinson C, Schwarz J, et al.
Patterns (N Y)
. 2024 Feb;
5(2):100910.
PMID: 38370125
Big genomic data and artificial intelligence (AI) are ushering in an era of precision medicine, providing opportunities to study previously under-represented subtypes and rare diseases rather than categorize them as...
6.
Pedersen L, Valenzuela Ripoll C, Ozcan M, Guo Z, Lotfinaghsh A, Zhang S, et al.
Med
. 2023 Nov;
4(12):928-943.e5.
PMID: 38029754
Background: Rapidly dividing cells are more sensitive to radiation therapy (RT) than quiescent cells. In the failing myocardium, macrophages and fibroblasts mediate collateral tissue injury, leading to progressive myocardial remodeling,...
7.
Terekhanova N, Karpova A, Liang W, Strzalkowski A, Chen S, Li Y, et al.
Nature
. 2023 Nov;
623(7986):432-441.
PMID: 37914932
Chromatin accessibility is essential in regulating gene expression and cellular identity, and alterations in accessibility have been implicated in driving cancer initiation, progression and metastasis. Although the genetic contributions to...
8.
Chen L, Shi V, Wang S, Sun L, Freeman R, Yang J, et al.
J Clin Invest
. 2023 Jun;
133(15).
PMID: 37279067
Patients with cancer who have high serum levels of squamous cell carcinoma antigen 1 (SCCA1, now referred to as SERPINB3) commonly experience treatment resistance and have a poor prognosis. Despite...
9.
Liu X, Hogg G, Zuo C, Borcherding N, Baer J, Lander V, et al.
Cancer Cell
. 2023 May;
41(6):1073-1090.e12.
PMID: 37236195
Chronic activation of inflammatory pathways and suppressed interferon are hallmarks of immunosuppressive tumors. Previous studies have shown that CD11b integrin agonists could enhance anti-tumor immunity through myeloid reprograming, but the...
10.
Chen L, Shi V, Wang S, Freeman R, Ruiz F, Jayachandran K, et al.
bioRxiv
. 2023 Feb;
PMID: 36778224
Radiotherapy is a commonly used cancer treatment; however, patients with high serum squamous cell carcinoma antigen (SCCA1/SERPINB3) are associated with resistance and poor prognosis. Despite being a strong clinical biomarker,...